University of Southern California, Department of Internal Medicine, USA.
Resuscitation. 2013 Feb;84(2):189-93. doi: 10.1016/j.resuscitation.2012.06.011. Epub 2012 Jun 26.
We evaluated the association between TH use and "dose" and cumulative vasopressor and inotrope requirement, survival, and neurologic outcome.
Therapeutic hypothermia (TH) improves outcome after cardiac arrest, but may increase vasopressor and inotrope requirements.
Chart review of in- and out-of-hospital cardiac arrests between 1/1/2005 and 3/15/2010. Data included demographic information, category of post-cardiac arrest illness severity ((I) awake, (II) coma (not following commands but intact brainstem responses)+mild cardiopulmonary dysfunction (SOFA [Sequential Organ Failure Assessment] cardiac+respiratory score<4), (III) coma+moderate-severe cardiopulmonary dysfunction (SOFA cardiac+respiratory score≥4), and (IV) coma without brainstem reflexes), cumulative vasopressor index (CVI), inotrope use, survival, and neurologic outcome. The "dose" of TH (hours*temperature below threshold) was calculated using thresholds of ≤34 °C and ≤35 °C. Data were analyzed using descriptive statistics, Student's t-test, Wilcoxon test, and chi-squared analysis. Linear and logistic regression evaluated the effect of hypothermia "dose" on total CVI, survival and neurologic outcome.
Among 361 comatose patients, 233 (65%) received TH. Vasopressor administration (measured by CVI) was higher in normothermic subjects (60.2% vs. 46.4%; p=0.016). Using a 34 °C threshold, SOFA respiratory subscore and PEA arrest predicted total CVI. Using a 35 °C threshold, severity of coma, SOFA respiratory subscore, PEA arrest and use of inotropic agents in addition to vasopressors predicted total CVI. Initial motor examination predicted survival and neurologic outcome, while TH "dose" did not.
TH delivery is not associated with vasopressor requirement. TH "dose" is not associated with total CVI, survival, or good outcome. Vasopressor or inotropic requirement should not contraindicate TH use.
我们评估了 TH 使用与“剂量”以及累积血管加压药和正性肌力药需求、生存率和神经结局之间的关系。
治疗性低温(TH)可改善心脏骤停后的预后,但可能增加血管加压药和正性肌力药的需求。
对 2005 年 1 月 1 日至 2010 年 3 月 15 日期间的院内和院外心脏骤停患者进行图表回顾。数据包括人口统计学信息、心脏骤停后疾病严重程度类别((I)清醒,(II)昏迷(不能遵从命令但脑干反应完整)+轻度心肺功能障碍(SOFA [序贯器官衰竭评估]心脏+呼吸评分<4),(III)昏迷+中度至重度心肺功能障碍(SOFA 心脏+呼吸评分≥4)和(IV)昏迷且无脑干反射)、累积血管加压药指数(CVI)、正性肌力药使用、生存率和神经结局。使用≤34°C 和≤35°C 的阈值计算 TH(小时*温度低于阈值)的“剂量”。使用描述性统计、学生 t 检验、Wilcoxon 检验和卡方分析进行数据分析。线性和逻辑回归评估了低温“剂量”对总 CVI、生存率和神经结局的影响。
在 361 名昏迷患者中,233 名(65%)接受了 TH。正常体温组血管加压药(通过 CVI 测量)的使用率更高(60.2%比 46.4%;p=0.016)。使用 34°C 阈值时,SOFA 呼吸亚评分和 PEA 骤停预测总 CVI。使用 35°C 阈值时,昏迷严重程度、SOFA 呼吸亚评分、PEA 骤停以及除血管加压药外还使用正性肌力药预测总 CVI。初始运动检查预测生存率和神经结局,而 TH“剂量”则没有。
TH 的使用与血管加压药的需求无关。TH“剂量”与总 CVI、生存率或良好结局无关。血管加压药或正性肌力药的需求不应成为 TH 使用的禁忌症。